KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected ...
It has been a roller coaster ride for Kymera Therapeutics KYMR stock this year. This clinical-stage biotechnology company is pioneering the field of targeted protein degradation (TPD) to develop drugs ...
Zacks Investment Research on MSN
KYMR skyrockets 82.4% in a year: More upside potential in 2026?
Kymera Therapeutics, Inc. KYMR has put up a stupendous performance over the past year. Shares of this clinical-stage ...
Kymera is eligible for up to $975 million in collaboration milestones, double digit royalties, and may opt-in to 50/50 development and profit share of KT-485 in the U.S. WATERTOWN, Mass., June 25, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback